| Expression pattern: |
UP |
| Associated gene: |
GPX4, U2AF65, Ago2 |
| Associated microRNA: |
miR-338-3p |
| Biological function: |
promotes NSCLC cell proliferation and inhibits ferroptosis |
| Molecular mechanism: |
circPVT1 sponges miR-338-3p to upregulate GPX4; U2AF65 binds and stabilizes circPVT1 |
| Biological pathway or process: |
proliferation (promotes); ferroptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Survival Analysis; Transfection; CCK8; Colony Formation Assay; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; FISH / smFISH; Actinomycin D / DRB Stability Assay; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry); H&E Staining |
| Clinical significance: |
high expression of circPVT1 was correlated with tumor size, TNM stage, and lymph node metastasis, and was associated with shorter overall survival |
| Description: |
circPVT1 is up-regulated in NSCLC and associated with worse clinical outcomes. It promotes proliferation and inhibits ferroptosis by acting as a ceRNA for miR-338-3p to increase GPX4 expression, and its abundance is enhanced by the RBP U2AF65 that binds and stabilizes circPVT1. |
| Confidence score: |
0.8227 |